Home > Press > Starpharma Holdings Ltd (ASX:SPL) Quarterly Activities Report to Dec 31, 2008
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) Quarterly Activities Report to Dec 31, 2008
Starpharma Holdings Ltd (ASX:SPL) Quarterly Activities Report to Dec 31, 2008
Melbourne, Australia | Posted on February 2nd, 2009
About Starpharma Holdings Ltd
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
For more information, please click here
Dr Jackie Fairley
Chief Executive Officer
Copyright © Starpharma Holdings Ltd
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.